[Survival of patients with HIV-related tuberculosis. Study of mortality during the first 9 months of treatment].
BACKGROUND
Among the individuals with tuberculosis who are infected with HIV a high degree of lethality has been found to exist during the first few weeks following the start of tuberculosis treatment. In this study, the survival of these individuals is studied within the framework of a retrospective cohort study.


METHODS
This study included 1135 subjects infected by HIV over age fifteen and residents of Barcelona who were registered by the Barcelona Tuberculosis Prevention and Control Program and were diagnoses within the 1988-1993 period. The variables analyzed were age, gender, former imprisonment, municipal district, risk group, percentage of T CD4+ lymphocytes, tuberculin test, AIDS diagnosis (as per CDC-1987), X-ray pattern, bacteriology and part of the body affected by the tuberculosis. The Cox semiparametric method, the Kaplan-Meir curves and the log-rank test were employed.


RESULTS
A 77% probability of survival during the first nine months was found to exist, with wide-ranging variations among the different subgroups. The only significant variables in the Cos multivariate model were AIDS, the percentage of T CD4+ lymphocytes and their interaction. The risk of death for an individual not having AIDS and a T CD4+ lymphocyte percentage of 14% or lower was 7.69 times higher than the risk of dying for an individual not having AIDS who had a T CD4+ lymphocyte percentage of above 14%.


CONCLUSIONS
The survival of those individuals having tuberculosis who are infected with HIV varies greatly. Those who died in the short term were diagnosed as having AIDS on starting the tuberculosis treatment and who also had a T CD4+ lymphocyte percentage of 14% or lower.
Falqués Casanovas
M
M
Departament d'Estadística, Universitat Politècnica de Catalunya, Barcelona.
Langohr
K
K
Gómez Melis
G
G
García de Olalla Rizo
P
P
Jansà López del Vallado
J M
JM
Caylà Buqueras
J A
JA
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D015331:Cohort Studies; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011329:Prisoners; D011336:Probability; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D014374:Tuberculin Test; D014376:Tuberculosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality*
D019380:Anti-HIV Agents; D000995:Antitubercular Agents